1
|
Thimoteo RRC, Neto PN, Costa DSS, da Mota Ramalho Costa F, Brito DC, Costa PRR, de Almeida Simão T, Dias AG, Justo G. Microarray data analysis of antileukemic action of Cinnamoylated benzaldehyde LQB-461 in Jurkat cell line. Mol Biol Rep 2024; 51:187. [PMID: 38270684 DOI: 10.1007/s11033-023-09030-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2023] [Accepted: 11/28/2023] [Indexed: 01/26/2024]
Abstract
BACKGROUND Leukemias stand out for being the main type of childhood cancer in the world. Current treatments have strong side effects for patients, and there is still a high rate of development of resistance to multidrug therapy. Previously, our research group developed a structure-activity study with novel synthetic molecules analogous to LQB-278, described as an essential molecule with in vitro antileukemic action. Among these analogs, LQB-461 stood out, presenting more significant antileukemic action compared to its derivative LQB-278, with cytostatic and cytotoxicity effect by apoptosis, inducing caspase-3, and increased sub-G1 phase on cell cycle analysis. METHODS AND RESULTS Deepening the study of the mechanism of action of LQB-461 in Jurkat cells in vitro, a microarray assay was carried out, which confirmed the importance of the apoptosis pathway in the LQB-461 activity. Through real-time PCR, we validated an increased expression of CDKN1A and BAX genes, essential mediators of the apoptosis intrinsic pathway. Through the extrinsic apoptosis pathway, we found an increased expression of the Fas receptor by flow cytometry, showing the presence of a more sensitive population and another more resistant to death. Considering the importance of autophagy in cellular resistance, it was demonstrated by western blotting that LQB-461 decreased LC-3 protein expression, an autophagic marker. CONCLUSIONS These results suggest that this synthetic molecule LQB-461 induces cell death by apoptosis in Jurkat cells through intrinsic and extrinsic pathways and inhibits autophagy, overcoming some mechanisms of cell resistance related to this process, which differentiates LQB-461 of other drugs used for the leukemia treatment.
Collapse
Affiliation(s)
| | | | - Debora S S Costa
- Instituto de Pesquisas Biomédicas - HNMD Marinha do Brazil, Rio de Janeiro, RJ, Brazil
| | | | | | - Paulo R R Costa
- Laboratório de Química Bioorgânica, UFRJ, Rio de Janeiro, RJ, Brazil
| | | | - Ayres G Dias
- Departamento de Química Orgânica, UERJ, Rio de Janeiro, RJ, Brazil
| | - Graça Justo
- Departamento de Bioquímica, UERJ, Rio de Janeiro, RJ, Brazil.
| |
Collapse
|
2
|
Pravdic Z, Vukovic NS, Gasic V, Marjanovic I, Karan-Djurasevic T, Pavlovic S, Tosic N. The influence of BCL2, BAX, and ABCB1 gene expression on prognosis of adult de novo acute myeloid leukemia with normal karyotype patients. Radiol Oncol 2023:raon-2023-0017. [PMID: 37078709 DOI: 10.2478/raon-2023-0017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2023] [Accepted: 03/30/2023] [Indexed: 04/21/2023] Open
Abstract
BACKGROUND Deregulation of the apoptotic process underlies the pathogenesis of many cancers, including leukemia, but is also very important for the success of chemotherapy treatment. Therefore, the gene expression profile of main apoptotic factors, such as anti-apoptotic BCL2 (B-cell lymphoma protein 2) and pro-apoptotic BAX (BCL2-associated X), as well as genes involved in the multi-drug resistance (ABCB1), could have significant impact on the prognosis and could be used as targets for specific therapy. PATIENTS AND METHODS We analyzed the expression of BCL2, BAX, and ABCB1 in bone-marrow samples collected at diagnosis from 51 adult patients with acute myeloid leukemia with normal karyotype (AML-NK) using real-time polymerase chain reaction method, and examined their prognostic potential. RESULTS Increased expression of BCL2 (BCL2 +) was associated with the presence of chemoresistance (p = 0.024), while patients with low BAX expression were more prone to relapse (p = 0.047). Analysis of the combined effect of BCL2 and BAX expression showed that 87% of patients with BAX/BCL2 low status were resistant to therapy (p = 0.044). High expression of ABCB1 was associated with BCL2 + status (p < 0.001), and with absence FLT3-ITD mutations (p = 0.019). CONCLUSIONS The present analysis of BCL2, BAX, and ABCB1 gene expression profiles is the first study focusing solely on AML-NK patients. Preliminary results showed that patients with high BCL2 expression are likely to experience resistance to chemotherapy, and may benefit from specific anti-BCL2 treatment. Further investigations conducted on a larger number of patients could elucidate actual prognostic significance of these genes in AML-NK patients.
Collapse
Affiliation(s)
- Zlatko Pravdic
- Clinic of Hematology, Clinical Center of Serbia, Belgrade, Serbia
| | - Nada Suvajdzic Vukovic
- Clinic of Hematology, Clinical Center of Serbia, Belgrade, Serbia
- School of Medicine, University of Belgrade, Serbia
| | - Vladimir Gasic
- Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Serbia
| | - Irena Marjanovic
- Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Serbia
| | | | - Sonja Pavlovic
- Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Serbia
| | - Natasa Tosic
- Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Serbia
| |
Collapse
|
3
|
Zhang L, Yang L, Luo Y, Dong L, Chen F. Acrylamide induced hepatotoxicity through oxidative stress: Mechanisms and interventions. Antioxid Redox Signal 2022; 38:1122-1137. [PMID: 36322716 DOI: 10.1089/ars.2022.0055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/21/2023]
Abstract
SIGNIFICANCE Acrylamide (AA) widely exists in the environment. Studies have demonstrated that AA has neurotoxicity and potential carcinogenicity in humans, and genotoxicity and severe hepatotoxicity in animals. As the critical metabolism organ for AA, the liver is the primary attacking target of AA. This review summarizes the recent advances in hepatotoxicity mechanism through AA-induced oxidative stress in rodent livers and hepatic cell lines, this is beneficial to assess risks of AA exposure and explore effective intervention methods for AA hepatotoxicity. RECENT ADVANCES Accumulating evidences have indicated that AA-induced oxidative stress is responsible for its hepatotoxicity. The changes in homological and biochemical indexes such as activities of hepatic antioxidant enzymes have been elucidated with the occurrence and development of oxidative stress. Also, the molecular mechanisms underlying AA-induced hepatotoxicity through oxidative stress have been mainly explained by apoptosis, inflammatory and autophagic pathways. CRITICAL ISSUES This review is focusing on the molecular mechanism of hepatotoxicity through AA-induced oxidative stress, this can provide a theoretical basis for the assessment of AA-induced health risk and finding potential intervention targets. FUTURE DIRECTIONS Epigenetic modifications like miRNAs and modulation of the gut microbiome involved in AA toxification pathway must be investigated, and will provide novel insights to unravel the toxification mechanism and intervention strategy for AA hepatotoxicity.
Collapse
Affiliation(s)
- Lujia Zhang
- China Agricultural University, 34752, Beijing, China;
| | - Liuqing Yang
- China Agricultural University, 34752, Beijing, China;
| | - Yinghua Luo
- China Agricultural University, 34752, Beijing, China;
| | - Li Dong
- China Agricultural University, 34752, Beijing, China;
| | - Fang Chen
- China Agricultural University, 34752, College of Food Science and Nutritional Engineering and Safety, Room 116, Food building, China Agricultural University, Haidian District, Beijing, China, 100094;
| |
Collapse
|
4
|
Leme KSV, Salvadori DMF. In vitro toxicogenomic activity of an MTA/salicylate-based endodontic sealer. Toxicol Rep 2022; 9:1076-1081. [DOI: 10.1016/j.toxrep.2022.05.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2021] [Revised: 04/30/2022] [Accepted: 05/02/2022] [Indexed: 10/18/2022] Open
|
5
|
Niu YN, Zeng Y, Zhong FF, Long SL, Ren DW, Qin X, Liu WJ. Salidroside overcomes dexamethasone resistance in T-acute lymphoblastic leukemia cells. Exp Ther Med 2021; 21:636. [PMID: 33968167 PMCID: PMC8097222 DOI: 10.3892/etm.2021.10068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2020] [Accepted: 03/19/2021] [Indexed: 01/18/2023] Open
Abstract
The aim of the present study was to analyze whether the use of salidroside (SAL) could overcome dexamethasone (DEX) resistance in T-acute lymphocytic leukemia cells. The human T-ALL DEX-resistant cell line, CEM-C1 and the DEX-sensitive cell line, CEM-C7 were used in the current study. The proliferation inhibition rates in these cells, treated with SAL and DEX alone, and in combination were detected using a Cell Counting Kit-8 assay, while the morphological changes of the cells were observed using an inverted microscope. Reverse transcription-quantitative PCR was used to detect the mRNA expression levels of the c-Myc and LC3 genes, while flow cytometry was used to detect the cell cycle distribution and the rate of apoptosis. In addition, western blot analysis was used to detect the protein expression levels of c-Myc, BCL-2, Bax, cleaved PARP and LC3. and acridine orange staining was used to detect the changes in acidic autophagy vesicles. It was found that SAL could effectively inhibit cell proliferation and induce apoptosis in the CEM-C1 and CEM-C7 cells. In addition, SAL promoted the induction of autophagy. The protein expression levels of c-Myc in the CEM-C1 cells were significantly higher compared with that in the CEM-C7 cells. SAL downregulated the mRNA expression levels of the c-Myc gene and protein in a dose-dependent manner. This suggested that SAL could inhibit the proliferation of the CEM-C1 and CEM-C7 cells, induce apoptosis and autophagy and overcome DEX resistance in the CEM-C1 cells. The mechanism may be associated with the downregulation of c-Myc.
Collapse
Affiliation(s)
- Ya-Na Niu
- Department of Pediatric Hematology, The Affiliated Hospital of Southwest Medical University and Birth Defects Clinical Medical Research Center of Sichuan Province, Luzhou, Sichuan 646000, P.R. China
| | - Yan Zeng
- Department of Pediatric Hematology, The Affiliated Hospital of Southwest Medical University and Birth Defects Clinical Medical Research Center of Sichuan Province, Luzhou, Sichuan 646000, P.R. China
| | - Fang-Fang Zhong
- Department of Pediatric Hematology, The Affiliated Hospital of Southwest Medical University and Birth Defects Clinical Medical Research Center of Sichuan Province, Luzhou, Sichuan 646000, P.R. China
| | - Si-Li Long
- Department of Pediatric Hematology, The Affiliated Hospital of Southwest Medical University and Birth Defects Clinical Medical Research Center of Sichuan Province, Luzhou, Sichuan 646000, P.R. China
| | - Dan-Wei Ren
- Department of Pediatric Hematology, The Affiliated Hospital of Southwest Medical University and Birth Defects Clinical Medical Research Center of Sichuan Province, Luzhou, Sichuan 646000, P.R. China
| | - Xiang Qin
- Department of Pediatric Hematology, The Affiliated Hospital of Southwest Medical University and Birth Defects Clinical Medical Research Center of Sichuan Province, Luzhou, Sichuan 646000, P.R. China
| | - Wen-Jun Liu
- Department of Pediatric Hematology, The Affiliated Hospital of Southwest Medical University and Birth Defects Clinical Medical Research Center of Sichuan Province, Luzhou, Sichuan 646000, P.R. China
| |
Collapse
|
6
|
Puglisi M, Molife LR, de Jonge MJ, Khan KH, Doorn LV, Forster MD, Blanco M, Gutierrez M, Franklin C, Busman T, Yang J, Eskens FA. A Phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors. Future Oncol 2021; 17:2747-2758. [PMID: 33849298 DOI: 10.2217/fon-2021-0140] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
Aim: This Phase I study investigated safety of navitoclax and docetaxel in patients (n = 41) with advanced solid tumors. Patients & methods: Two navitoclax plus docetaxel dosing schedules (21 and 28 days) were evaluated. Maximum tolerated dose, dose-limiting toxicities and preliminary antitumor activity were assessed. Results: Ten (24%) patients experienced dose-limiting toxicities; dose-escalation cohorts: n = 7 (21-day schedule: n = 5; 28-day schedule: n = 2) and 21-day expanded safety cohort: n = 3. Navitoclax 150-mg days 1-5 every 21 days with docetaxel 75 mg/m2 day 1 was the maximum tolerated dose and optimal schedule. Adverse events included thrombocytopenia (63%), fatigue (61%), nausea (59%) and neutropenia (51%). Four confirmed partial responses occurred. Conclusion: Navitoclax 150-mg orally once/day was safely administered with docetaxel. Myelosuppression limited dose escalation; antitumor activity was observed. Clinical trial registration: NCT00888108 (ClinicalTrials.gov).
Collapse
Affiliation(s)
- Martina Puglisi
- Drug Development Unit, Institute of Cancer Research/The Royal Marsden, Downs Road, Sutton, Surrey, SM2 5PT, UK
| | - L Rhoda Molife
- Drug Development Unit, Institute of Cancer Research/The Royal Marsden, Downs Road, Sutton, Surrey, SM2 5PT, UK
| | - Maja Ja de Jonge
- Department of Medical Oncology, Erasmus MC Cancer Institute, PO Box 2040, 3000 CA Rotterdam, The Netherlands
| | - Khurum H Khan
- UCL Cancer Institute, University College London Hospital, Gower Street, London, WC1E 6BT, UK
| | - Leni van Doorn
- Department of Medical Oncology, Erasmus MC Cancer Institute, PO Box 2040, 3000 CA Rotterdam, The Netherlands
| | - Martin D Forster
- UCL Cancer Institute, University College London Hospital, Gower Street, London, WC1E 6BT, UK
| | - Montserrat Blanco
- Drug Development Unit, Institute of Cancer Research/The Royal Marsden, Downs Road, Sutton, Surrey, SM2 5PT, UK
| | - Martin Gutierrez
- John Theurer Cancer Center, Hackensack University Medical Center, 92 2nd St, Hackensack, NJ 07601, USA
| | | | - Todd Busman
- AbbVie, Inc, 1 North Waukegan Road, North Chicago, IL 60064, USA
| | - Jianning Yang
- AbbVie, Inc, 1 North Waukegan Road, North Chicago, IL 60064, USA
| | - Ferry Alm Eskens
- Department of Medical Oncology, Erasmus MC Cancer Institute, PO Box 2040, 3000 CA Rotterdam, The Netherlands
| |
Collapse
|
7
|
Alzate JM, Montoya-Florez LM, Pérez JE, Rocha NS, Pedraza-Ordonez FJ. The role of the multi-drug resistance 1, p53, b cell lymphoma 2, and bcl 2-associated X genes in the biologic behavior and chemotherapeutic resistance of canine transmissible venereal tumors. Vet Clin Pathol 2019; 48:730-739. [PMID: 31777108 DOI: 10.1111/vcp.12805] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2018] [Revised: 02/02/2019] [Accepted: 02/16/2019] [Indexed: 11/27/2022]
Abstract
BACKGROUND Canine transmissible venereal tumors (CTVTs) generally have different cytomorphologic subtypes and phases of progression. Some tumors have variable biologic behavior including a progressive increase in tumor aggressiveness and variable responses to chemotherapy. This behavior is partially due to high p-glycoprotein expression by tumor cells, which leads to the expulsion of chemotherapeutic drugs. Other possible causes include changes in pro- and anti-apoptotic genes from the BCL-2 family and DNA repair systems, which are associated with the p53 gene family. OBJECTIVES We aimed to determine the relative expression of the multi-drug resistance 1 (MDR1), p53, b-cell lymphoma 2 (BCL2), and bcl 2-associated X (BAX) genes in CTVT before and after therapy and establish a relationship with treatment responses, cytomorphologic patterns, and tumor progression identified with histopathology. METHODS RT-qPCR was performed on 21 CTVT tumor samples before and after initiating chemotherapy to determine specific gene expression. Normal canine testicular tissue was used as a negative control for all experiments. RESULTS MDR1 expression was decreased before and after initiating vincristine therapy in CTVT tumor tissues compared with normal canine testicular tissue; p53 and BAX were overexpressed at both time points compared with normal tissue, and no statistical differences were seen between the different morphologic types. However, BAX expression was decreased in the group with quick therapeutic responses but was still overexpressed compared with normal testicular tissue. In the group with the slowest chemotherapeutic responses, BCL2 was overexpressed. CONCLUSION The findings of this study showed a relative increase in MDR1 gene expression in response to chemotherapy and higher expression in plasmacytoid CTVTs compared with the other cytomorphologic patterns. BCL2 overexpression was related to a favorable prognosis, and p53, BAX, and BCL2 were expressed independent of the cytomorphologic CTVT type. All of the genes were expressed independent of tumor progression, as noted on histopathology.
Collapse
Affiliation(s)
- Juliana M Alzate
- Faculty of Agricultural Sciences, Veterinary Medicine Department, Universidad de Pamplona, Pamplona, Colombia
| | - Luis M Montoya-Florez
- Faculty of Veterinary Medicine, Universidad Nacional de Colombia, Bogotá, Colombia.,Research Group in Veterinary Medicine and Husbandry - GIDIMEVETZ, Pedagogical and Technological University of Colombia, Tunja, Colombia
| | - Jorge E Pérez
- Basic Sciences Department, Universidad de Caldas, Manizales, Colombia
| | - Noeme S Rocha
- Laboratory of Investigative and Comparative Pathology, FMVZ-UNESP, Botucatu, Brazil
| | - Francisco J Pedraza-Ordonez
- Research Group in Veterinary Pathology, Animal Health Department, Universidad de Caldas, Manizales, Colombia
| |
Collapse
|
8
|
LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR-29b-3p. Cell Death Dis 2019; 10:106. [PMID: 30728351 PMCID: PMC6365572 DOI: 10.1038/s41419-018-1219-0] [Citation(s) in RCA: 69] [Impact Index Per Article: 13.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2018] [Revised: 11/07/2018] [Accepted: 11/14/2018] [Indexed: 02/07/2023]
Abstract
Radiotherapy, chemotherapy, autologous/allogeneic stem cell transplantation, and targeted drug therapy are currently available therapeutic options for multiple myeloma (MM), but the clinical outcome remains unsatisfactory owing to frequent occurrence of drug resistance. Anti apoptosis is one of the main mechanisms to mediate drug resistance. Studies have shown that MCL-1 plays a key role in the growth of cancer cells “escaping” drug attacks, but the underlying mechanism remains unclear. Our previous study demonstrated that lncRNA H19 was highly expressed in the serum of MM patients. Bioinformatics predicts that miR-29b-3p is the downstream target gene, and MCL-1 is the downstream target protein of miR-29b-3p. Therefore, we speculated that MCL-1 may be involved in the occurrence of drug resistance through epigenetics. On the basis of these previous findings, the present study was intended to explore the biological function of H19, interactions between the downstream target genes, and the effect of H19 on BTZ resistance of myeloma cells. In addition, in vivo experiments we have also confirmed that H19 promoted tumor growth and may develop resistance to bortezomib partly. It was found that H19 reduced cell sensitivity to the chemotherapeutic drug BTZ by working as a miRNA sponge to inhibit the expression of miR-29b-3p, enhance MCL-1 transcriptional translation and inhibit apoptosis. These findings may help gain insights into the molecular mechanism of acquired BTZ resistance and develop new drug targets for the clinical treatment of MM.
Collapse
|